About Vitrolife
Pioneering the science of human fertility, Vitrolife is a Swedish medtech company whose products are used in IVF clinics across more than 110 countries. Founded in 1994 and headquartered in Gothenburg, Sweden, the group has grown into one of the most recognised names in assisted reproductive technology, supplying the consumables, media and equipment that laboratories depend on throughout the IVF process.
The company's portfolio centres on IVF culture media, time-lapse incubation systems, and associated laboratory consumables. Its time-lapse technology, which allows embryologists to monitor embryo development continuously without disturbing the culture environment, has become widely adopted in fertility clinics worldwide. Vitrolife is listed on Nasdaq Stockholm, reflecting its standing as a significant publicly traded entity in the European medtech sector.
A major expansion came through the acquisition of Igenomix in 2021, broadening Vitrolife's capabilities into reproductive genetics, including preimplantation genetic testing services used to assess embryo chromosomal status before transfer. This move extended the group's reach well beyond physical laboratory products and into genomic diagnostics for fertility treatment.
Vitrolife operates its own manufacturing and research facilities, and its scientific teams publish regularly in peer-reviewed reproductive medicine literature. The company serves fertility specialists, reproductive biologists, and IVF laboratory directors, positioning itself as a full-cycle partner from fertilisation through embryo selection and transfer.
Further information is available at vitrolife.com.
